The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 1, 2007, Pages 27-32

  Jonsson, Gisli ^a   Abdelnoor, Michael ^a   Seljeflot, Ingebjorg ^a   Arnesen, Harald ^a   Hostmark, Arne T ^a   Kjeldsen, Sverre E ^a   Os, Ingrid ^a   Westheim, Arne S ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myocardial infarction; Atenolol; Beta adrenergic receptor blockers; Carvedilol; Oxidized low density lipoproteins; Thiobarbituric acid reactive substances; Vitamin E

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; OXIDIZED LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; WARFARIN;

ACUTE HEART INFARCTION; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; BLOOD CLOT LYSIS; BLOOD SAMPLING; CHOLESTEROL BILE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; THERAPY EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

ANTIOXIDANTS; ATENOLOL; CARBAZOLES; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPANOLAMINES; PROSPECTIVE STUDIES; TIME;

EID: 33846579639     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802bdd8c     Document Type: Article

References (49)

1. Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91:7A-11A.
2. Cross CE, Halliwell B, Borish ET, et al. Oxygen radicals and human disease. Ann Intern Med. 1987;107:526-545.
3. Kritharides L, Stocker R. The use of antioxidant supplements in coronary heart disease. Atherosclerosis. 2002;164:211-219.
4. Yue T-L, Cheng H-Y, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
5. Ruffolo RR Jr, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol. 1998;32:S22-S30.
6. Jonsson G, Abdelnoor M, Müller C, et al. A comparison of the two β-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. A single centre, randomized study of 232 patients. Cardiology. 2005;103:148-155.
7. O'Donnell VB. Free radicals and lipid signaling in endothelial cells. Antioxid Redox Signal. 2003;5:195-203.
8. Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109:IV6-IV19.
9. Li D, Yang B, Mehta JL. Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Am J Physiol. 1998;275:H568-H576.
10. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein showa positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1960.
11. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41:360-370.
12. Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA. 1999;281:1718-1721.
13. Walter MF, Jacob RF, Jeffers B, et al. PREVENT study. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol. 2004;44:1996-2002.
14. Singh RB, Pella D, Neki NS, et al. Mechanisms of acute myocardial infarction study (MAMIS). Biomed Pharmacother. 2004;58:S111-S115.
15. Jonsson G, Fossum E, Kjeldsen SE, et al. Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. Blood Press. 2002;11:377-384.
16. Kosugi H, Kojima T, Kikugawa K. Thiobarbituric acid-reactive substances from peroxidized lipids. Lipids. 1989;24:873-881.
17. Brude IR, Drevon CA, Hjermann I, et al. Peroxidation of LDL from combined hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants. Arterioscler Thromb Vasc Biol. 1997;17:2576-2588.
18. Bernstein R, Müller C, Midtbø K, et al. Cardiac left ventricular function before and during early thyroxine treatment in severe hypothyroidism. J Intern Med. 1991;230:493-500.
19. Folland ED, Hamilton GW, Larson SM, et al. The radionuclide ejection fraction: a comparison of three radionuclide techniques with contrast angiography. J Nucl Med. 1977;18:1159-1166.
20. Altman DG. Practical statistics for medical research. London: Chapman and Hall. 1991.
21. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323:1123-1124.
22. Maggi E, Marchesi E, Covini D, et al. Protective effect of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low-density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol. 1996;27:532-538.
23. Parik T, Allikmets K, Teesalu R, et al. Oxidative stress and hyperinsulinaemia in essential hypertension: different facets of increased risk. J Hypertens. 1996;14:407-410.
24. Yasunari K, Maeda K, Nakamura M, et al. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med. 2004;116:460-465.
25. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
26. Ignarro LJ, Byrns RE, Buga GM, et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res. 1987;61:866-879.
27. Fratta Pasini A, Garbin U, Nava MC, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589-596.
28. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511-514.
29. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor nitric oxide production. Circulation. 2000;102:677-684.
30. Cavalca V, Cighetti G, Bamonti F, et al. Oxidative stress and homocysteine in coronary artery disease. Clin Chem. 2001;47:887-892.
31. Chiu HC, Jeng JR, Shieh SM. Increased oxidizability of plasma low-density lipoprotein from patients with coronary artery disease. Biochim Biophys Acta. 1994;1225:200-208.
32. Shimada K, Mokuno H, Matsunaga E, et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis. 2004;174:343-347.
33. Nordin Fredrikson G, Hedblad B, Berglund G, et al. Plasma oxidized LDL: a predictor for acute myocardial infarction? J Intern Med. 2003;253:425-429.
34. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:844-888.
35. Holvoet P, Stassen JM, Van Cleemput J, et al. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18:100-107.
36. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
37. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85:753-766.
38. Stocker R. Dietary and pharmacological antioxidants in atherosclerosis. Curr Opin Lipidol. 1999;10:589-597.
39. Riemersma RA, Wood DA, Macintyre CCA, et al. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet. 1991;337:1-5.
40. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99:2645-2651.
41. Sakabe K, Fukuda N, Wakayama K, et al. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol. 2004;94:497-500.
42. McAlpine HM, Cobbe SM. Neuroendocrine changes in acute myocardial infarction. Am J Med. 1988;84:61-66.
43. Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohumoral activation following acute myocardial infarction. Am Heart J. 1993;126:1068-1076.
44. Lombardi F, Sandrone G, Spinnler MT, et al. Heart rate variability in the early hours of an acute myocardial infarction. Am J Cardiol. 1996:77:1037-1044.
45. Graham LN, Smith PA, Stoker JB, et al. Time course of sympathetic neural hyperactivity after uncomplicated acute myocardial infarction. Circulation. 2002;106:793-797.
46. Graham LN, Smith PA, Huggett RJ, et al. Sympathetic drive in anterior and inferior uncomplicated acute myocardial infarction. Circulation. 2004;109:2285-2289.
47. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol. 1998;31:1352-1356.
48. Katz SD. Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol. 1997;12:259-264.
49. Kaul N, Siveski-Iliskovic N, Hill M, et al. Free radicals and the heart. J Pharmacol Toxicol Methods. 1993;30:55-67.